Compass Therapeutics (CMPX) Stock Declines as Tovecimig Trial Misses Overall Survival Endpoint Despite Strong PFS and ORR
Compass Therapeutics (CMPX) Stock Declines as Tovecimig Trial Misses Overall Survival Endpoint Despite Strong PFS and ORR
Compass Therapeutics reported Phase 2/3 COMPANION-002 trial results for tovecimig plus paclitaxel in second-line biliary tract cancer, meeting primary endpoint with 17.1% ORR vs. 5.3% for paclitaxel alone (p=0.031) 1 3 . Key secondary endpoint of median PFS improved to 4.7 months vs. 2.6 months (HR 0.44, p<0.0001) 1 . Overall survival did not meet statistical significance due to 54% crossover from control arm to tovecimig; crossover patients had 12.8 months median OS vs. 6.1 months for non-crossover (HR 0.54, p=0.04) 1 . CMPX shares were down around 11% in pre-market trading ahead of the data release on April 27, 2026 2 . Trial enrolled 168 patients randomized 2: 1; company plans BLA submission based on efficacy 1 . Sources: 1. https://www.stocktitan.net/sec-filings/CMPX/8-k-compass-therapeutics-inc-reports-material-event-e60495fdf769.html 2. https://stocktwits.com/news-articles/markets/equity/cmpx-stock-retail-buzzing-ahead-of-cancer-drug-trial-update/cZBNZa7Re2t 3...
- Get link
- X
- Other Apps